Ateb, a privately held company that seeks ways to improve patient care and enhance pharmacy operations, announced that pharmacy veteran Mark Gregory, R. Ph., will join its team to assist with business development.
Fresh from Tuesday morning’s Health Mart Annual Meeting at 2014 McKesson ideaShare, attendees eagerly gathered to take part in the Health Mart University Live sessions that addressed key topics for independent pharmacy success.
After speaking at the Health Mart Annual Meeting Tuesday morning, Tony Willoughby, Health Mart’s chief pharmacist, sat down with DSN to talk about how pharmacies can drive adherence and excel in today’s changing healthcare environment.
Even before the official start of this year’s McKesson ideaShare conference, the Gaylord Palms Resort and Convention Center was buzzing with attendees eager to take advantage of the robust lineup of continuing education courses held on Sunday and Monday.
The Food and Drug Administration on Thursday announced the approval of Ruconest, a recombinant C1-Esterase inhibitor product for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema.
About 30% of top-performing OTC drugs today were once prescription-only medications noted Dave Wendland, VP Hamacher Resource Group, on Thursday during a videocast hosted by GMDC titled "Rx-to-OTC: Getting it Right at Retail."
RetireSafe, a grassroots organization advocating on behalf of America’s seniors on Tuesday released a survey finding that seniors overwhelmingly support strong patient safeguards for biosimilar medications.
Former Republican Speaker of the House J. Dennis Hastert last week wrote an editorial for the Washington Times supporting the use of such tamper-resistant pseudoephedrine products as Acura Pharmaceuticals' Nexafed and Westport Pharmaceuticals' Zephrex-D.
Giant Eagle last week added prescription blood-pressure medications lisinopril and lisinopril HCTZ to the list of several antibiotics that the chain provides for free to its patients, according to a report inthe Columbus Dispatch.
Although the pace of approvals for new orphan drugs — medicines that treat relatively rare conditions — have increased in the United States and Europe in recent years, patients are facing growing challenges accessing those drugs, a newly completed study released last week by the Tufts Center for the Study of Drug Development at Tufts University has concluded.
Teva Pharmaceuticals on Monday announced that the Food and Drug Administration has accepted the company's new drug application for albuterol multi-dose dry-powder inhaler, a breath-actuated dry-powder inhaler for the treatment or prevention of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease.
Anacor Pharmaceuticals announced that the Food and Drug Administration has approved the company's new drug application for Kerydin (tavaborole) topical solution, 5% — an antifungal approved for the topical treatment of onychomycosis of the toenails.